PDF herunterladen
Semin Thromb Hemost 2012; 38(04): 412-420
DOI: 10.1055/s-0032-1304715
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Future of Antiphospholipid Antibody Testing

Philip G. de Groot
1   Department of Clinical Chemistry and Haematology, University Medical Center, Utrecht, The Netherlands
,
Rolf T. Urbanus
1   Department of Clinical Chemistry and Haematology, University Medical Center, Utrecht, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. März 2012 (online)

    Lizenzen und Reprints

Abstract

The presence of antiphospholipid antibodies (aPL) is essential to diagnose the antiphospholipid syndrome (APS). Three assays are available to detect the presence of these autoantibodies, but all three assays suffer from several important drawbacks. First, the assays lack standardization because the results of the assay partially depend on the laboratory that performs the assay. Second, we do not know whether the assays detect the autoantibody population responsible for the clinical manifestations that characterize the syndrome. Finally, the assays do not predict the risk of recurrence. There is an absolute need for novel assays that generate prognostic information that can be used for a more tailored treatment of patients with APS. In 2011, important information became available on the protein against which the autoantibodies are directed, β2-glycoprotein I (β2GPI). Based on the progress we have made in our understanding of the physiology of β2GPI, it should be possible to design assays that can better predict the consequences of the presence of aPL in the circulation.

Keywords

lupus anticoagulant - antiphospholipid antibodies - β2-glycoprotein I - anticardiolipin antibodies
 

  • References

  • 1 Miyakis S, Lockshin MD, Atsumi D , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
    CrossrefPubMedGoogle Scholar
  • 2 Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood 2009; 114 (10) 2020-2030
    CrossrefPubMedGoogle Scholar
  • 3 Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296 (15) 1858-1866
    CrossrefPubMedGoogle Scholar
  • 4 Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE ; UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002; 119 (2) 364-369
    CrossrefPubMedGoogle Scholar
  • 5 Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream?. Semin Thromb Hemost 2008; 34 (4) 340-346
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 6 Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A ; Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-glycoprotein I activity. Thromb Res 2007; 120 (1) 127-133
    CrossrefPubMedGoogle Scholar
  • 7 Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118 (4) 548-557
    CrossrefPubMedGoogle Scholar
  • 8 Favaloro EJ, Wong RC, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thomson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing. Semin Thromb Hemost 2005; 31 (1) 73-84
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
    CrossrefPubMedGoogle Scholar
  • 10 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (5) 1827-1832
    CrossrefPubMedGoogle Scholar
  • 11 Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102 (8) 2717-2723
    CrossrefPubMedGoogle Scholar
  • 12 Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6 (2) 399-401
    CrossrefPubMedGoogle Scholar
  • 13 Hlatky MA, Greenland P, Arnett DK , et al; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119 (17) 2408-2416
    CrossrefPubMedGoogle Scholar
  • 14 Urbanus RT, de Groot PG. Antiphospholipid antibodies—we are not quite there yet. Blood Rev 2011; 25 (2) 97-106
    CrossrefPubMedGoogle Scholar
  • 15 Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002; 119 (4) 1005-1010
    CrossrefPubMedGoogle Scholar
  • 16 Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006; 4 (1) 44-49
    PubMedGoogle Scholar
  • 17 Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8 (11) 998-1005
    CrossrefPubMedGoogle Scholar
  • 18 Levine SR, Brey RL, Tilley BC , et al; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291 (5) 576-584
    CrossrefPubMedGoogle Scholar
  • 19 Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011; 270 (2) 110-122
    CrossrefPubMedGoogle Scholar
  • 20 Reddel SW, Wang YX, Krilis SA. Anti-beta2-glycoprotein I autoantibodies require an antigen density threshold, consistent with divalent binding. Lupus 2003; 12 (1) 37-45
    CrossrefPubMedGoogle Scholar
  • 21 de Laat B, Derksen RHWM, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change. Blood 2006; 107 (5) 1916-1924
    CrossrefPubMedGoogle Scholar
  • 22 Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95 (26) 15542-15546
    CrossrefPubMedGoogle Scholar
  • 23 Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 2000; 15 (2) 91-96
    CrossrefPubMedGoogle Scholar
  • 24 de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105 (4) 1540-1545
    CrossrefPubMedGoogle Scholar
  • 25 Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56 (1) 280-290
    CrossrefPubMedGoogle Scholar
  • 26 De Laat B, Derksen RH, Reber G , et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost 2011; 9 (1) 149-153
    CrossrefPubMedGoogle Scholar
  • 27 Neville C, Rauch J, Kassis J , et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost 2009; 101 (1) 100-107
    PubMedGoogle Scholar
  • 28 Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?. Curr Rheumatol Rep 2011; 13 (1) 59-69
    CrossrefPubMedGoogle Scholar
  • 29 Favaloro EJ, Bonar R, Sioufi J , et al; RCPA QAP in Haematology. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Haematology. Semin Thromb Hemost 2005; 31: 49-58
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 30 Erkan D, Harrison MJ, Levy R , et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56 (7) 2382-2391
    CrossrefPubMedGoogle Scholar
  • 31 van Goor MP, Alblas CL, Leebeek FW, Koudstaal PJ, Dippel DW. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke?. Acta Neurol Scand 2004; 109 (6) 410-415
    CrossrefPubMedGoogle Scholar
  • 32 Pengo V. Antiphospholipid syndrome: interpretation of laboratory data. J Thromb Haemost 2011; 9 (2) 402-403
    CrossrefPubMedGoogle Scholar
  • 33 Ruffatti A, Tonello M, Del Ross T , et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96 (3) 337-341
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 34 Pengo V, Ruffatti A, Legnani C , et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (2) 237-242
    CrossrefPubMedGoogle Scholar
  • 35 Pengo V, Ruffatti A, Legnani C , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
    CrossrefPubMedGoogle Scholar
  • 36 Shoenfeld Y, Krause I, Kvapil F , et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003; 23 (5) 377-383
    CrossrefPubMedGoogle Scholar
  • 37. de Laat B, van Os G, Ninivaggi M , et al. Anti-domain I antibodies have a prothrombotic character on coagulation by inhibiting the anticoagulant effect of beta2-glycoprotein. J Throm Haemost 2010; 9 (Suppl. 02) O-TU-93 (abstract)
    PubMedGoogle Scholar
  • 38 Simmelink MJA, Derksen RHWM, Arnout J, De Groot PG. A simple method to discriminate between β2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1 (4) 740-747
    CrossrefPubMedGoogle Scholar
  • 39 de Laat HB, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104 (12) 3598-3602
    CrossrefPubMedGoogle Scholar
  • 40 De Laat B, Derksen RH, Reber G , et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost 2011; 9 (1) 149-153
    CrossrefPubMedGoogle Scholar
  • 41 Pengo V, Brocco T, Biasiolo A, Rampazzo P, Carraro P, Zamarchi R. Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. Blood 1999; 94 (11) 3814-3819
    PubMedGoogle Scholar
  • 42 Rand JH, Wu XX, Andree HA , et al. Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism. N Engl J Med 1997; 337 (3) 154-160
    CrossrefPubMedGoogle Scholar
  • 43 Rand JH, Wu X-X, Lapinski R , et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104 (9) 2783-2790
    CrossrefPubMedGoogle Scholar
  • 44 Hunt BJ, Wu XX, de Laat B, Arslan AA, Stuart-Smith S, Rand JH. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol 2011; 205 (5) 485 , e17–e23
    PubMedGoogle Scholar
  • 45 de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109 (4) 1490-1494
    CrossrefPubMedGoogle Scholar
  • 46 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66 (6) 629-632
    PubMedGoogle Scholar
  • 47 Simmelink MJA, Derksen RHWM, Arnout J, De Groot PG. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1 (4) 740-747
    CrossrefPubMedGoogle Scholar
  • 48 Rao LV, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996; 88 (11) 4173-4182
    PubMedGoogle Scholar
  • 49 Atsumi T, Ieko M, Bertolaccini ML , et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000; 43 (9) 1982-1993
    CrossrefPubMedGoogle Scholar
  • 50 Devreese KMJ, Hoylaerts MF. Autoantibodies against prothrombin and prothrombin phosphatidylserine complex: a diagnostic tool for the antiphospholipid syndrome?. J Thromb Haemost 2011; 9 (Suppl. 02) P-MO-354
    PubMedGoogle Scholar
  • 51 Shen YM, Lee R, Frenkel E, Sarode R. IgA antiphospholipid antibodies are an independent risk factor for thromboses. Lupus 2008; 17 (11) 996-1003
    CrossrefPubMedGoogle Scholar
  • 52 Mehrani T, Petri M. Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol 2011; 38 (1) 64-68
    CrossrefPubMedGoogle Scholar
  • 53 Sweiss NJ, Bo R, Kapadia R , et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS ONE 2010; 5 (8) e12280
    CrossrefPubMedGoogle Scholar
  • 54 Toschi V, Motta A, Castelli C , et al. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus. Haemostasis 1993; 23 (5) 275-283
    PubMedGoogle Scholar
  • 55 Mcintyre JA, Wagenknecht DR. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun 2000; 15 (2) 185-193
    CrossrefPubMedGoogle Scholar
  • 56 Sanmarco M, Gayet S, Alessi MC , et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007; 97 (6) 949-954
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 57 Rolla R, Vidali M, Serino R, Pergolini P, Albano E, Bellomo G. Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity. Clin Exp Immunol 2007; 149 (1) 63-69
    CrossrefPubMedGoogle Scholar
  • 58 Alessandri C, Sorice M, Bombardieri M , et al. Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res Ther 2006; 8 (6) R180
    CrossrefPubMedGoogle Scholar
  • 59 Matsuura E, Hughes GR, Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008; 7 (7) 558-566
    CrossrefPubMedGoogle Scholar
  • 60 Ao W, Zheng H, Chen XW, Shen Y, Yang CD. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int 2011; 31 (7) 865-869
    CrossrefPubMedGoogle Scholar
  • 61 Dieudé M, Correa JA, Neville C , et al. Association of autoantibodies to heat-shock protein 60 with arterial vascular events in patients with antiphospholipid antibodies. Arthritis Rheum 2011; 63 (8) 2416-2424
    CrossrefPubMedGoogle Scholar
  • 62 Hughes GRV, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13 (3) 486-489
    PubMedGoogle Scholar
  • 63 Agar C, van Os GM, Mörgelin M , et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116 (8) 1336-1343
    CrossrefPubMedGoogle Scholar
  • 64 Biasiolo A, Rampazzo P, Brocco T, Barbero F, Rosato A, Pengo V. [Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus 1999; 8 (2) 121-126
    CrossrefPubMedGoogle Scholar
  • 65 Agar C, de Groot PG, Mörgelin M , et al. β2-glycoprotein I: a novel component of innate immunity. Blood 2011; 117 (25) 6939-6947
    CrossrefPubMedGoogle Scholar
  • 66 Passam FH, Rahgozar S, Qi M , et al. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood 2010; 116 (11) 1995-1997
    CrossrefPubMedGoogle Scholar
  • 67 Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modifications of beta2-glycoprotein I. J. Thromb Haemost 2011; 9 (Suppl. 01) 275-282
    PubMedGoogle Scholar
  • 68 Ioannou Y, Zhang JY, Qi M , et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum 2011; 63 (9) 2774-2782
    CrossrefPubMedGoogle Scholar
  • 69 Holers VM, Girardi G, Mo L , et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195 (2) 211-220
    CrossrefPubMedGoogle Scholar
  • 70 Girardi G, Berman J, Redecha P , et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112 (11) 1644-1654
    CrossrefPubMedGoogle Scholar
  • 71 Stewart MW, Etches WS, Gordon PA. Antiphospholipid antibody-dependent C5b-9 formation. Br J Haematol 1997; 96 (3) 451-457
    CrossrefPubMedGoogle Scholar
  • 72 Gropp K, Weber N, Reuter M , et al. β2-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 2011; 118 (10) 2774-2783
    CrossrefPubMedGoogle Scholar
  • 73 Arad A, Proulle V, Furie RA, Furie BC, Furie B. β2-glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011; 117 (12) 3453-3459
    CrossrefPubMedGoogle Scholar
  • 74 Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011; 10 (10) 609-616
    CrossrefPubMedGoogle Scholar